

SEP 8 2003

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Hiroaki Hashimoto Manager, engineering Management Section Eizo Nanao Corporation 153 Shimokashiwano-cho, Matto-shi Ishikawa-ken, 924-8566 JAPAN

Re: K032026

Trade/Device Name: RadiForce G11, RadiForce G31, & RadiForce G51

Regulation Number: 21 CFR 892.2050

Regulation Name: Picture archiving and communication system

Regulatory Class: II Product Code: 90 LLZ Dated: August 4, 2003 Received: August 8, 2003

Dear Mr. Hashimoto:

This letter corrects our substantially equivalent letter of August 27, 2003 regarding the address and contact information.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent for the indications for use stated in the enclosure to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21)

CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4564. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at their toll free number (800) 638-2041 or at (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Nancy C. Brogdon

Director, Division of Reproductive, Abdominal, and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

510(k) Number (I	f known):	K0320	26				
Device Name	 46 cm (18.1 inch) Monochrome LCD Monitor, RadiForce G11 53 cm (20.8 inch) Monochrome LCD Monitor, RadiForce G31 54 cm (21.3 inch) Monochrome LCD Monitor, RadiForce G51 						
Indications for Us	se:						
Monochrome LCD diagnosis of X-ray	Monitor, F y or MRI, e	RadiForce G1 tc.	11, G31 and G	51 are inte	nded to be 1	used in dis	playing for
(PLEASE DO NO	OT WRITE	BELOW TH	IS LINE-CON	TINUE ON	I ANOTHE	R PAGE IF	NEEDED)
	Concu	rrence of CD	RH, Office of I	evice Eval	uation (ODI	Ξ)	
		•					ing w
	_						
Prescription Use (Per 21CFR 801	e .109)	Dani	OR IA la	Ove	er-The-Cour	nter Use	
		(Division Sign Division of Re and Radiologic	productive, Abdo	ominal,	•		
		510(k) Numbe	r	2026			